Navigation Links
ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
Date:2/6/2009

MENLO PARK, Calif., Feb. 6 /PRNewswire/ -- ROXRO announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead investigational prescription drug candidate, ROX-888, for the management of acute moderate to severe pain. ROX-888 is an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory drug (NSAID), designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute pain relief, without the risk of addiction or the other negative effects of narcotics. The NDA package for ROX-888 includes data from more than 1,000 subjects and 14 clinical trials. If approved, ROX-888 is expected to be the first non-narcotic intranasal analgesic indicated for the management of acute moderate to severe pain.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090206/AQF506)

"This milestone for ROX-888 is a significant business accomplishment for ROXRO. Our virtual operating structure has enabled us to develop an extensive NDA package for our lead product candidate in an extremely capital-efficient manner," said Roberto Rosenkranz, Chief Executive Officer of ROXRO. "We believe that ROX-888 has the potential to fill important needs in the large and growing market for acute moderate to severe pain treatments. Currently approved forms of ketorolac are already well accepted by the physician community for in-hospital use, and we believe physicians will quickly adopt this investigational intranasal form of ketorolac as a new therapeutic option to replace or minimize oral opioid use for take-home prescriptions. As we plan a potential product launch at the end of 2009, pending FDA approval, we are now seeking a commercialization partner to help us realize the full benefit of this drug."

ROX-888 has been tested in four controlled efficacy studies, and met the primary endpoints in each trial. Additionally, ROX-888 has demonstrated a good safety profile, as would be expected with short-term use of an NSAID. Mild, transient nasal irritation was the most common side-effect of ROX-888 usage. As with other NSAIDs, ROX-888 should not be used in patients with renal insufficiency, active peptic ulcers, or a history of GI bleeding.

"ROX-888 could fulfill a compelling medical need for both clinicians and patients -- an analgesic that provides potent, rapid-onset pain control while minimizing the potential for abuse and the negative side-effects perceived to be associated with narcotic pain relievers," said Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Development, Inc. and lead investigator for ROXRO's second Phase 3 study. "If approved, the nasal spray product, formulated for convenient use, will provide patients pain relief at home or in an out-patient or ambulatory setting, without the need for injections or intravenous administration."

About ROX-888

ROX-888 is a novel, investigational intranasal formulation of the potent non-steroidal anti-inflammatory drug (NSAID) ketorolac. Currently, ketorolac is most often administered in the hospital setting as an intramuscular injection or intravenously for the short-term treatment of moderate to severe pain. The analgesic efficacy of ketorolac is primarily associated with the inhibition of prostaglandin synthesis via non-selective inhibition of COX-1/COX-2 enzymes. Based on clinical studies conducted to date, ROX-888 is expected to allow patients to receive the same benefits of hospital-strength ketorolac in a convenient form that can be used at home. Formulated as an easy-to-use spray, ROX-888 is rapidly absorbed through the nasal mucosa, achieving peak blood levels as fast as an intramuscular injection. The pharmacokinetic properties of ROX-888 have been demonstrated in clinical trials to provide rapid relief of acute moderate to severe pain.

About ROXRO

ROXRO PHARMA, Inc. is a late-stage specialty pharmaceutical company developing hospital strength acute pain products for convenient use by patients in the home setting. The company is led by a seasoned management team that has discovered, developed and commercialized several pain and cardiovascular medicines that are widely prescribed today. http://www.roxropharma.com


'/>"/>
SOURCE ROXRO PHARMA, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ROXRO PHARMA Marks 5th Year Of Cafe Scientifique Sponsorship
2. Nu Skin Enterprises Announces 5 Percent Increase in Quarterly Dividend
3. Kmart Announces Voluntary Recall of Certain Items Containing Peanuts Sold at Super Kmart Bakery Locations
4. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
5. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008
6. United American Healthcare Corporation Announces Fiscal 2009 Second Quarter Results
7. Medical Device Consultants, Inc. (MDCI) Announces Senior Staff Changes and Promotions
8. Medical Device Consultants, Inc. (MDCI) Announces Clinical Services Staff Promotions
9. CVS/pharmacy Announces Plans for New Distribution Center in Southern New York
10. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
11. ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: